Sunovion Pharmaceuticals Inc.
84 Waterford Drive
About Sunovion Pharmaceuticals Inc.
Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people living with serious medical conditions. Our vision is to lead the way to a healthier world, and we believe scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything we do, we have charted new paths to life-transforming treatments reflecting ongoing investments in R&D and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.
298 articles with Sunovion Pharmaceuticals Inc.
Sunovion To Present Clinical Efficacy, Safety And Health-Related Quality Of Life Outcomes Data From Its Respiratory Franchise At The American Thoracic Society 2017 International Conference
Sunovion Announces Positive Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD
Sunovion To Present Data On Aptiom (Eslicarbazepine Acetate) At American Academy of Neurology 2017 Annual Meeting
Sunovion Announces Utibron Neohaler (Indacaterol/Glycopyrrolate) Inhalation Powder Now Available In The United States
Sunovion Submits Supplemental New Drug Application To FDA For Use Of APTIOM (Eslicarbazepine Acetate) For The Treatment Of Partial-Onset Seizures In Children 4 Years Of Age And Older
Sunovion Announces Positive Topline Results From Study Evaluating Latuda (Lurasidone HCL) In Children And Adolescents With Bipolar Depression
Demi Lovato, Sunovion And Leading Advocacy Organizations Release Mental Health Documentary As Part Of Be Vocal Initiative
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo
Sunovion Enters Into License Agreement For Three Approved Treatment Options For People With COPD In The U.S.
Sunovion Initiates SEP-363856 Phase II Program For Patients With Schizophrenia Or Parkinson’s Disease Psychosis
Demi Lovato, Sunovion And Leading Advocacy Organizations Launch The Be Vocal Collection In Partnership With Getty Images To Encourage The Realistic Portrayal Of Mental Health
Sunovion Announces Positive Clinical Study Results For Latuda (Lurasidone HCL) In Adolescents With Schizophrenia
The American College of Chest Physicians And Sunovion Announce Strategic Initiative Focused On The Importance Of Drug Delivery In The Management Of COPD
Sunovion Announces FDA Filing Acceptance Of New Drug Application For SUN-101/Eflow For The Treatment Of Patients With Chronic Obstructive Pulmonary Disease (COPD)